Marisa Jennings, MD
Psychiatry · Minot, NDNPI 1902067366
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.2% of the total across 125 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in ND with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 125 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$353
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$321
- AbbVie$297
- Alkermes, Inc.$247
- Teva Pharmaceuticals USA, Inc.$219
- Takeda Pharmaceuticals U.S.A., Inc.$196
- plus $488 from 10 others
What the payments were for
- Food & beverage$2,01995%
- Education$1015%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 19 | $353 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $321 |
| AbbVie(2 entities) | 22 | $297 |
| Alkermes, Inc. | 16 | $247 |
| Teva Pharmaceuticals USA, Inc. | 8 | $219 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $196 |
| Sunovion Pharmaceuticals Inc. | 9 | $89 |
| Neurocrine Biosciences, Inc. | 5 | $88 |
| Merck | 5 | $80 |
| Otsuka America Pharmaceutical, Inc. | 5 | $77 |
| Collegium Pharmaceutical, Inc. | 3 | $59 |
| E.r. Squibb & Sons, L.L.C. | 1 | $30 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| Sage Therapeutics, LLC | 1 | $15 |
| Eisai Inc. | 1 | $15 |
How this compares
$2,120 in reported general payments places this provider in the 90th percentile of 63 psychiatry providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AristadaAripiprazole Lauroxil | 11 | $33,051 |
| LybalviOlanzapine/Samidorphan Malate | 14 | $23,270 |
| RexultiBrexpiprazole | 16 | $22,673 |
| VraylarCariprazine Hcl | 11 | $16,261 |
| Lurasidone Hcl | 32 | $11,840 |
| FetzimaLevomilnacipran Hcl | 13 | $6,478 |
| DayvigoLemborexant | 15 | $5,015 |
| Bupropion XlBupropion Hcl | 178 | $4,556 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 21 | $4,497 |
| Quetiapine Fumarate | 222 | $3,343 |
| Aripiprazole | 89 | $3,194 |
| Paliperidone ErPaliperidone | 17 | $3,128 |
| Carbamazepine ErCarbamazepine | 13 | $2,881 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 33 | $2,745 |
| Escitalopram Oxalate | 111 | $2,658 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Aristada, Lybalvi | $247 | $56,32125 claims |
| AbbVieVraylar, Fetzima | $297 | $22,74024 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $77 | $22,67316 claims |
| Eisai Inc.Dayvigo | $15 | $5,01515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 63 psychiatry providers in North Dakota.
Other psychiatry in Minot
- Ronny MeunierMinot$33K
- Wayne MartinsenMinot$2K
- Elizabeth OhikuMinot$1K
- Adam JangulaMinot$390
- Michael RayelMinot$248
- Lauren-Alyssa WakeMinot$246
- Deidre RichardsMinot$202
- Jackie LongMinot$152
- Asha PatelMinot$0
- James MitchellFargo$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.